Huntleigh Advisors Inc. Has $2.23 Million Stock Position in Abbott Laboratories (NYSE:ABT)

by · The Cerbat Gem

Huntleigh Advisors Inc. lifted its holdings in shares of Abbott Laboratories (NYSE:ABT – Free Report) by 2.2% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 16,810 shares of the healthcare product maker’s stock after acquiring an additional 360 shares during the quarter. Huntleigh Advisors Inc.’s holdings in Abbott Laboratories were worth $2,230,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. Redwood Park Advisors LLC bought a new stake in Abbott Laboratories in the 4th quarter valued at $25,000. NewSquare Capital LLC lifted its position in shares of Abbott Laboratories by 78.4% during the 4th quarter. NewSquare Capital LLC now owns 239 shares of the healthcare product maker’s stock valued at $27,000 after acquiring an additional 105 shares during the period. JCIC Asset Management Inc. bought a new stake in shares of Abbott Laboratories during the 1st quarter valued at $32,000. WealthTrak Capital Management LLC bought a new stake in shares of Abbott Laboratories during the 4th quarter valued at $28,000. Finally, Rialto Wealth Management LLC bought a new stake in shares of Abbott Laboratories during the 4th quarter valued at $29,000. 75.18% of the stock is currently owned by institutional investors.

Insider Activity at Abbott Laboratories

In other news, Director Sally E. Blount sold 2,600 shares of the firm’s stock in a transaction on Wednesday, April 30th. The stock was sold at an average price of $129.66, for a total value of $337,116.00. Following the completion of the transaction, the director directly owned 34,058 shares of the company’s stock, valued at $4,415,960.28. This trade represents a 7.09% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.46% of the stock is owned by insiders.

Abbott Laboratories Stock Down 0.3%

Shares of Abbott Laboratories stock opened at $133.70 on Friday. The stock’s 50-day moving average is $133.20 and its 200 day moving average is $128.16. The firm has a market cap of $232.61 billion, a price-to-earnings ratio of 17.34, a PEG ratio of 2.55 and a beta of 0.73. The company has a debt-to-equity ratio of 0.26, a current ratio of 1.78 and a quick ratio of 1.27. Abbott Laboratories has a one year low of $99.71 and a one year high of $141.23.

Abbott Laboratories (NYSE:ABT – Get Free Report) last issued its quarterly earnings results on Wednesday, April 16th. The healthcare product maker reported $1.09 EPS for the quarter, beating analysts’ consensus estimates of $1.07 by $0.02. Abbott Laboratories had a return on equity of 19.01% and a net margin of 31.89%. The company had revenue of $10.36 billion during the quarter, compared to the consensus estimate of $10.38 billion. Equities research analysts anticipate that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, August 15th. Stockholders of record on Tuesday, July 15th will be issued a $0.59 dividend. This represents a $2.36 dividend on an annualized basis and a dividend yield of 1.77%. The ex-dividend date is Tuesday, July 15th. Abbott Laboratories’s payout ratio is currently 30.61%.

Wall Street Analyst Weigh In

ABT has been the subject of a number of recent analyst reports. Barclays upped their target price on Abbott Laboratories from $158.00 to $159.00 and gave the company an “overweight” rating in a research report on Thursday, April 17th. Morgan Stanley boosted their price target on Abbott Laboratories from $117.00 to $127.00 and gave the stock an “equal weight” rating in a report on Thursday, April 17th. Leerink Partners started coverage on Abbott Laboratories in a report on Monday, June 16th. They set a “market perform” rating and a $143.00 price target for the company. Raymond James Financial boosted their price target on Abbott Laboratories from $132.00 to $142.00 and gave the stock an “outperform” rating in a report on Thursday, April 17th. Finally, Leerink Partnrs raised Abbott Laboratories to a “hold” rating in a report on Monday, June 16th. Six analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $142.61.

View Our Latest Report on ABT

Abbott Laboratories Profile

(Free Report)

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.

Featured Stories

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT – Free Report).